Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide
- PMID: 16434128
- DOI: 10.1016/j.vaccine.2005.12.034
Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide
Abstract
Apical membrane antigen 1 (AMA1) has been shown to be a promising malaria vaccine candidate. The multiallelic AMA1-C1 vaccine currently in Phase 1 trials in the US and Mali contains an equal mixture of the ectodomain portion of recombinant AMA1 from the FVO and 3D7 clones of Plasmodium falciparum, formulated on Alhydrogel. It is hoped that inclusion of a human-optimized CpG oligodeoxynucleotide (ODN) (CPG 7909) with our existing AMA1-C1/Alhydrogel vaccine will lead to a higher concentration of functional AMA1-C1 antibodies. Preclinical studies were performed in mice, rats and guinea pigs to assess the safety, immunogenicity and functionality of the immune response to AMA1-C1 with Alhydrogel + CPG 7909 compared to antigen with Alhydrogel alone. Day 42 mean anti-AMA1 ELISA titer values derived from individual animals were compared between Alhydrogel and Alhydrogel + CPG 7909 groups at each antigen dose for each species. Sera from Alhydrogel + CPG 7909 groups displayed significantly higher antibody titers (P < 0.025) than their comparable Alhydrogel alone group. Mouse IgG isotype analysis showed that AMA1-C1/Alhydrogel induced a predominately Th2 type response while AMA1-C1/Alhydrogel + CPG 7909 gave a mixed Th1/Th2 type response. When tested for functional activity by in vitro inhibition of parasite invasion, IgG isolated from serum pools of AMA1-C1/Alhydrogel + CPG 7909 animals was more effective against both FVO and 3D7 parasites than an equal concentration of IgG from animals receiving vaccines adjuvanted with Alhydrogel alone. These promising preclinical results have recently led to the start of a Phase 1 trial in the US.
Similar articles
-
Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.Vaccine. 2007 Jul 20;25(29):5343-7. doi: 10.1016/j.vaccine.2007.05.007. Epub 2007 May 25. Vaccine. 2007. PMID: 17566616 Free PMC article.
-
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.PLoS One. 2008 Aug 13;3(8):e2940. doi: 10.1371/journal.pone.0002940. PLoS One. 2008. PMID: 18698359 Free PMC article. Clinical Trial.
-
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.Vaccine. 2009 Dec 9;27(52):7292-8. doi: 10.1016/j.vaccine.2009.10.087. Epub 2009 Oct 27. Vaccine. 2009. PMID: 19874925 Free PMC article. Clinical Trial.
-
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.Infect Immun. 2005 Jun;73(6):3677-85. doi: 10.1128/IAI.73.6.3677-3685.2005. Infect Immun. 2005. PMID: 15908397 Free PMC article. Clinical Trial.
-
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.Vaccine. 2017 Oct 27;35(45):6218-6227. doi: 10.1016/j.vaccine.2017.09.027. Epub 2017 Sep 22. Vaccine. 2017. PMID: 28947345 Clinical Trial.
Cited by
-
Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.Vaccine. 2017 Sep 5;35(37):4952-4959. doi: 10.1016/j.vaccine.2017.07.076. Epub 2017 Jul 31. Vaccine. 2017. PMID: 28774566 Free PMC article.
-
Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1.PLoS One. 2012;7(6):e36996. doi: 10.1371/journal.pone.0036996. Epub 2012 Jun 4. PLoS One. 2012. PMID: 22675476 Free PMC article.
-
Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.Clin Vaccine Immunol. 2014 Sep;21(9):1215-23. doi: 10.1128/CVI.00205-14. Epub 2014 Jun 25. Clin Vaccine Immunol. 2014. PMID: 24964808 Free PMC article.
-
Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation.Sci Rep. 2015 Mar 12;5:8925. doi: 10.1038/srep08925. Sci Rep. 2015. PMID: 25762407 Free PMC article.
-
Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.Vaccine. 2007 Jul 20;25(29):5343-7. doi: 10.1016/j.vaccine.2007.05.007. Epub 2007 May 25. Vaccine. 2007. PMID: 17566616 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources